Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

NCT00095563 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

High-grade Salivary Gland Carcinoma
High-grade Salivary Gland Mucoepidermoid Carcinoma
Low-grade Salivary Gland Carcinoma
Low-grade Salivary Gland Mucoepidermoid Carcinoma
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Salivary Gland Cancer
Salivary Gland Acinic Cell Tumor
Salivary Gland Adenocarcinoma
Salivary Gland Adenoid Cystic Carcinoma
Salivary Gland Malignant Mixed Cell Type Tumor

Interventions

DRUG: lapatinib ditosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)